Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol
Cumulative Skin Irritation Study Evaluating the Skin Irritancy Potential of Topical Analgesic Vovilup Spray Containing a Combination of Diclofenac, Menthol, Methyl Salicylate and Linseed Oil and Comparing it With a Marketed Formulation - Iodex Ultragel
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Healthy male or female volunteers aged at least 18 years.
Good general, physical and mental health in the opinion of the investigator or medically qualified designee:
- No clinically significant and relevant abnormalities in medical history or upon physical examination.
- Absence of any condition that could affect the volunteer's safety or well being or their ability to understand and follow study procedures and requirements.
- Healthy volunteers who do not have excessive hair on the volar aspect of the forearm(s).
- Healthy volunteers should understand and be willing to fully comply with all study procedures and restrictions.
- Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
- Females of childbearing potential, using an effective contraceptive method for at least one month before the beginning of the study, and willing to use throughout the study
Exclusion Criteria
- Volunteers having recent history (within one year) of alcohol or other substance abuse as determined by medical history.
- Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit.
- Previous participation in similar study with similar products.
- Volunteer has any visible skin disease at the site of application that, in the opinion of the investigator, will interfere with the skin assessments.
- Volunteer has current or relevant previous history of serious, severe or unstable physical or psychiatric illness, or medical disorders, such as current or previous history of hepatic or renal diseases (impairment) or peptic ulcer as determined by medical history.
- Volunteer has a history of hypersensitivity (e.g. asthma, bronchospasm, rhinitis, urticaria, nasal polyps) to aspirin, diclofenac, other non steroidal anti-inflammatory drugs (NSAIDs), menthol or any of the excipients in the test product(s).
- Volunteer is receiving systemic or topical NSAIDs, other oral or topical analgesics or antihistamine within 3 days of visit 1, or other medication (such as corticosteroids within 3 weeks of visit 1) which, in the opinion of the investigative personnel, will interfere with the study results.
- Female volunteers who are pregnant, planning to become pregnant during the study, or are breast-feeding.
- Female volunteers who have positive pregnancy test.
- Volunteers who are employees of the sponsor or study site or an immediate family member (e.g. partner, offspring, parents, siblings or sibling's offspring) of such employees.
- Any skin disorder at the test site that in the investigator's judgement can affect the readings of the test result
- Any concomitant medications that in the investigator's judgement can confound or alter test results or evaluation of adverse events.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Topical Spray
Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
|
Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
|
|
Experimental: Topical Gel
Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
|
Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
|
|
Other: Saline
|
Saline
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Mean cumulative irritation score
Time Frame: 7 days
|
7 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 202201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Irritation
-
NCT01887808Completed
-
NCT01821274Unknown
-
NCT06810856CompletedSkin Sensitization | Skin Irritation
-
NCT01892423Completed
-
NCT03397862CompletedSkin Irritation | Sensitization
-
NCT01892410Completed
-
NCT02645110UnknownSkin Irritation | Hand Hygiene
-
NCT01922700CompletedCough | Irritation in Throat | Irritation in Skin | Lacrimation
-
NCT01887860Completed
Clinical Trials on Saline
-
NCT03280745CompletedCardiovascular Diseases | Valvular Heart Disease
-
NCT04213508UnknownOtorhinolaryngologic Diseases | Rhinosinusitis
-
NCT05611736CompletedApical Periodontitis | Post Operative Pain | Dental Pulp Necroses
-
NCT06069336Completed
-
NCT03143231CompletedLength of Hospital Stay